Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease
...l developmentspecialist that in-licenses promising biologics and small moleculedrug candidates. Debiopharm develops its products for globalregistration and maximum commercial potential for out-licensing topharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development...Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
...ionalcombinations of ERBITUX with chemotherapy and biologics in patientswith this aggressive cancer for whom treatment options remainacutely limited. Other ERBITUX data presented at ASCO included the following: -- Two randomized studies evaluated ERBITUX combined withoxaliplatin-based chemotherapy in first l...Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal
... and enhance the retention of anti-cancerdrugs and biologics within tumours. The drug becomes entrainedwithin the HA matrix and the HA binds to receptors located on thetumour cell resulting in more of the drug being delivered to thetumour. Preclinically, the HyACT(TM) technology has demonstratedimproved delive...Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for the Treatment of Psoriasis
...oriasis. Consequently, recently approvedanti-TNF-? biologics have proven effective; however, they have tobe administered frequently and at high doses and are thereforeassociated with substantial manufacturing costs and inconveniencefor patients. CYT007-TNFQb is a therapeutic vaccine in development for thetrea...... biopharmaceutical company with smallmolecules and biologics product candidates for the treatment ofinfectious diseases, cancer and inflammatory diseases. TheCompany's clinical development programs include PICTOVIR(TM) forHIV infection and VGX-410C for chronic HCV infection, both of whichare currently in Phase......determine whether there is anopportunity to file a biologics license application (BLA) on thebasis of these results along with appropriate commitments toconduct further clinical investigations to support the efficacy ofOncophage in renal cell carcinoma. Antigenics also plans to explorethe need for further clin...Dendreon Announces Presentation of Data at American Urological Association Annual Meeting
... aclinical trial for PROVENGE will not support our biologics licenseapplication, the risk that the FDA may interpret data differentlythan we do or require more data or a more rigorous analysis of datathan expected, the risk that the FDA will not approve a biologicslicense application for a therapeutic, the ris...Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment of HCV
...l developmentspecialist that in-licenses promising biologics and small moleculedrug candidates. Debiopharm develops its products for globalregistration and maximum commercial potential for out-licensing topharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development......ical developmentcompany that in-licenses promising biologics and small moleculedrug candidates. Debiopharm develops its products for globalregistration and maximum commercial potential for out-licensing topharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development...